Table 1 Clinical and pathological characteristics of ER+ breast cancer patients with advanced disease treated with combined CDK4/6i and endocrine treatment from pilot and validation cohorts according to p-AKT levels.

Parameters	Pilot				Validation				Pilot vs. validation
Parameters	p-AKT low	p-AKT high	N	p^a	p-AKT low	p-AKT high	N	p^a	pilot	validation	N	p^a
Age at starting CDK4/6i
≤50	1	1	2	0.33	5	2	7	0.63	2	7	9	0.65
>50	13	2	15	0.33	62	15	77	0.63	15	77	92	0.65
Site of relapse^b
Soft tissue	9	1	10	0.53	20	5	25	0.13	10	25	35	0.37
Bone	3	2	5		34	5	39		5	39	44
Viscera	2	0	2		13	7	20		2	20	22
No metastatic sites
1	4	1	5	0.86	18	6	24	0.62	5	24	29	0.16
2	7	1	8		19	3	22		8	22	30
≥3	3	1	4		30	8	38		4	38	42
Chemotherapy^c
No	9	1	10	0.54	37	8	45	0.60	10	45	55	0.79
Yes	5	2	7	0.54	30	9	39	0.60	7	39	46	0.79
Time to recurrence (years)
≤5	7	3	10	0.28	28	5	33	0.35	10	33	43	0.29
1–10	4	0	4		16	7	23		4	23	27
>10	3	0	3		23	5	28		3	28	31
Total	14	3	17		67	17	84		17	84	101

Quick links

Search